Alpha DaRT
Cutaneous Squamous Cell Carcinoma & Skin Metastases
Key Facts
About Alpha Tau Medical
Alpha Tau Medical's mission is to revolutionize solid tumor treatment through its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform. The company has achieved significant clinical validation, securing FDA Breakthrough Device Designations for skin/oral cavity SCC and recurrent glioblastoma, and is now executing a global, multi-indication clinical trial strategy. Its strategy focuses on addressing high-unmet-need patient populations with localized, unresectable tumors and exploring combinations with immunotherapies for metastatic disease.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical's mission is to revolutionize solid tumor treatment through its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform. The company has achieved significant clinical validation, securing FDA Breakthrough Device Designations for skin/oral cavity SCC and recurrent glioblastoma, and is now executing a global, multi-indication clinical trial strategy. Its strategy focuses on addressing high-unmet-need patient populations with localized, unresectable tumors and exploring combinations with immunotherapies for metastatic disease.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical's mission is to revolutionize solid tumor treatment through its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform. The company has achieved significant clinical validation, securing FDA Breakthrough Device Designations for skin/oral cavity SCC and recurrent glioblastoma, and is now executing a global, multi-indication clinical trial strategy. Its strategy focuses on addressing high-unmet-need patient populations with localized, unresectable tumors and exploring combinations with immunotherapies for metastatic disease.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical's mission is to revolutionize solid tumor treatment through its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform. The company has achieved significant clinical validation, securing FDA Breakthrough Device Designations for skin/oral cavity SCC and recurrent glioblastoma, and is now executing a global, multi-indication clinical trial strategy. Its strategy focuses on addressing high-unmet-need patient populations with localized, unresectable tumors and exploring combinations with immunotherapies for metastatic disease.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical's mission is to revolutionize solid tumor treatment through its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform. The company has achieved significant clinical validation, securing FDA Breakthrough Device Designations for skin/oral cavity SCC and recurrent glioblastoma, and is now executing a global, multi-indication clinical trial strategy. Its strategy focuses on addressing high-unmet-need patient populations with localized, unresectable tumors and exploring combinations with immunotherapies for metastatic disease.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical's mission is to revolutionize solid tumor treatment through its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform. The company has achieved significant clinical validation, securing FDA Breakthrough Device Designations for skin/oral cavity SCC and recurrent glioblastoma, and is now executing a global, multi-indication clinical trial strategy. Its strategy focuses on addressing high-unmet-need patient populations with localized, unresectable tumors and exploring combinations with immunotherapies for metastatic disease.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical's mission is to revolutionize solid tumor treatment through its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform. The company has achieved significant clinical validation, securing FDA Breakthrough Device Designations for skin/oral cavity SCC and recurrent glioblastoma, and is now executing a global, multi-indication clinical trial strategy. Its strategy focuses on addressing high-unmet-need patient populations with localized, unresectable tumors and exploring combinations with immunotherapies for metastatic disease.
View full company profileAbout Alpha Tau Medical
Alpha Tau Medical's mission is to revolutionize solid tumor treatment through its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform. The company has achieved significant clinical validation, securing FDA Breakthrough Device Designations for skin/oral cavity SCC and recurrent glioblastoma, and is now executing a global, multi-indication clinical trial strategy. Its strategy focuses on addressing high-unmet-need patient populations with localized, unresectable tumors and exploring combinations with immunotherapies for metastatic disease.
View full company profile